ClinicalTrials.gg
RecruitingNCT07449338Updated May 28, 2026

Prospective Cohort Study of Response and Tolerability of Accelerated Intermittent Theta-burst Stimulation (1W-AiTBS)

An observational study in Depression, sponsored by Vastra Gotaland Region. Recruiting at 3 sites in Sweden. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-28.

Sponsored by Vastra Gotaland Region · Observational

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
36
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 183 studies in Depression with a site in Sweden — 34 open to participants now, 47 under way, 1 of them phase 3. Depression · Sweden.

Planned enrollment
24th of 26
36 · median 140
Started
2026
with 5 others
Observational
27 of 183
8 open now
Primary completion
2027-03
later than 34 of 46 live
Registered
177th of 183
by date
Lead sponsor
6 of 183
Vastra Gotaland Region

Among the 183 studies in Depression with a site in Sweden, this one is the 24th largest by planned enrollment of the 26 observational ones that give a count, is one of 6 that started in 2026, is one of 27 observational ones, reaches primary completion later than 34 of the 46 other live ones, and was the 177th registered.

Depression

8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.

Browse Depression studies →

Open to participants now

34 of the 183 studies in Depression with a site in Sweden are open now. Recruiting first, the newest first:

28 more — sign in →

All 34 open studies →

A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →

Who these studies take

Of the 1,098 Depression studies recruiting now, 475 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 315 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 183 studies in Depression with a site in Sweden, or all of them as a file.
02

Study summary

Intermittent theta-burst stimulation (iTBS), a variant of repetitive transcranial magnetic stimulation (rTMS), is a well-documented treatment for depression. The aim of this study is to evaluate the effectiveness of an accelerated iTBS protocol (1W-AiTBS) in routine clinical practice. In the accelerated protocol, patients receive 600 pulses per session, for a total of 30 sessions administered over 5-14 treatment days. Patient inclusion will take place over a maximum period of 1.5 years, with a maximum sample size of 150 patients. The target sample size is at least 36 patients. Patients will complete self-rating questionnaires at screening, before and after treatment, and at 6 weeks, 12 weeks, and 6 months from the first day of treatment.

03

Conditions studied

  • Depression

Browse trials for

Keywords

  • iTBS
  • rTMS
  • depression
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients referred for AiTBS treatment at participating study sites will be invited to participate in the study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • diagnosis of depression verified through a Mini International Neuropsychiatric Interview (M.I.N.I.)
  • provision of signed form
  • indication for TMS is depression

Exclusion criteria

Exclusion Criteria:

  • conductive ferromagnetic or other metals implanted in the head or within 30 cm of the treatment coil
  • implanted device that is activated or controlled in any way by physiological signals
  • implanted mediation pumps
  • intracardiac lines, even when removed
  • any condition that seriously increases the risk of non-compliance or loss of follow-up
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
36 participants (estimated)
Target follow-up
6 Months
Patient registry
Yes

Groups and cohorts

  • 1W-AiTBS

    Magnetic pulses of 80% of visual motor threshold applied in triplets of 50 Hz bursts, repeated at 5 Hz; 2 seconds on and 8 seconds off; 600 pulses per session; total duration of 3 min 20 s over the left DLPFC (F3), given in a maximum of 8 sessions per day (\>15 min interval), total of 30 treatments on total of 10 week days.

    Device: iTBS (intermittent theta-burst stimulation)

Interventions

  • DeviceiTBS (intermittent theta-burst stimulation)

    The iTBS treatment is a type of rTMS (repetitive transcranial magnetic stimulation), delivered with MagPro R30 stimulator and a conventional cool-B65 coil. The iTBS treatment is applied to over the dorsolateral prefrontal cortex using a standardized measuring of the anatomical landmark F3 from the 10-20 positioning system. The coil is positioned with the handle at in a 45 degree angle from the midline. The centre of the butterfly is placed towards the patient head.

06

What researchers measure

Primary outcomes

  1. Difference in MADRS-S from baseline to six weeks after first iTBS treatment

    The self-rating version of the Montgomery-Asberg Depression Rating Scale (MADRS-S) is a rating scale (0-54 points), where a higher score indicates worse depressive symptoms

    Time frame: 6 weeks

Secondary outcomes

  1. Difference in MADRS-S from baseline to after last iTBS treatment

    The self-rating version of the Montgomery-Asberg Depression Rating Scale (MADRS-S) is a rating scale (0-54 points), where a higher score indicates worse depressive symptoms

    Time frame: 2 weeks

  2. Difference in MADRS-S from baseline to twelve weeks after first iTBS treatment

    The self-rating version of the Montgomery-Asberg Depression Rating Scale (MADRS-S) is a rating scale (0-54 points), where a higher score indicates worse depressive symptoms

    Time frame: 12 weeks

  3. Difference in MADRS-S from baseline to six months after first iTBS treatment

    The self-rating version of the Montgomery-Asberg Depression Rating Scale (MADRS-S) is a rating scale (0-54 points), where a higher score indicates worse depressive symptoms

    Time frame: 6 months

  4. Difference in SDS from baseline to twelve weeks after first iTBS treatment

    The Sheehan Disability Scale (SDS) is a self-rating assessment (0-30 points), where a higher score indicates more pronounced functional impairment

    Time frame: 12 weeks

  5. Difference in SDS from baseline to six months after first iTBS treatment

    The Sheehan Disability Scale (SDS) is a self-rating assessment (0-30 points), where a higher score indicates more pronounced functional impairment

    Time frame: 6 months

  6. Difference in EQ-VAS from baseline to after last iTBS treatment

    The EQ-5D visual analogue scale (EQ-VAS) is a self-rating assessment (VAS 0-100 points), where a higher (VAS) score indicates a higher health-related quality of life

    Time frame: 2 weeks

  7. Difference in EQ-VAS from baseline to six weeks after first iTBS treatment

    The EQ-5D visual analogue scale (EQ-VAS) is a self-rating assessment (VAS 0-100 points), where a higher (VAS) score indicates a higher health-related quality of life

    Time frame: 6 weeks

  8. Difference in EQ-VAS from baseline to twelve weeks after first iTBS treatment

    The EQ-5D visual analogue scale (EQ-VAS) is a self-rating assessment (VAS 0-100 points), where a higher (VAS) score indicates a higher health-related quality of life

    Time frame: 12 weeks

  9. Difference in EQ-VAS from baseline to six months after first iTBS treatment

    The EQ-5D visual analogue scale (EQ-VAS) is a self-rating assessment (VAS 0-100 points), where a higher (VAS) score indicates a higher health-related quality of life

    Time frame: 6 months

  10. Difference in reported potential side effects from baseline to after last iTBS treatment

    A patient-reported form including the most commonly reported side effects of rTMS.

    Time frame: 2 weeks

  11. Difference in reported potential side effects from baseline to six weeks after first iTBS treatment

    A patient-reported form including the most commonly reported side effects of rTMS.

    Time frame: 6 weeks

  12. Difference in reported potential side effects from baseline to twelve weeks after first iTBS treatment

    A patient-reported form including the most commonly reported side effects of rTMS.

    Time frame: 12 weeks

  13. Difference in reported potential side effects from baseline to six months after first iTBS treatment

    A patient-reported form including the most commonly reported side effects of rTMS.

    Time frame: 6 months

  14. rTMS associated pain experience

    A patient-reported form rating experience of pain (scale 1 to 10) during rTMS treatment. Performed after last treatment series

    Time frame: 2 weeks

  15. Number of patients in remission after last iTBS treatment

    A patient with a MADRS-S score of \< 10 is considered to be in remission

    Time frame: 2 weeks

  16. Number of patients in remission six weeks after first iTBS treatment

    A patient with a MADRS-S score of \< 10 is considered to be in remission

    Time frame: 6 weeks

  17. Number of patients in remission twelve weeks after first iTBS treatment

    A patient with a MADRS-S score of \< 10 is considered to be in remission

    Time frame: 12 weeks

  18. Number of patients in remission six months after first iTBS treatment

    A patient with a MADRS-S score of \< 10 is considered to be in remission

    Time frame: 6 months

07

Study locations

3 of 3 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Mar 2027, 12 months after the start.

Of 463 non-industry observational studies under Depression, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 63. This study's planned 12 months is below that.

Counting every sponsor, half of 496 studies reached it within 32 months; a quarter within 13 and three quarters within 61.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2026
First posted
Mar 4, 2026
StartActual
Mar 1, 2026
Primary completionEst.
Mar 1, 2027
CompletionEst.
Mar 1, 2027
Last update
May 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07449338
Responsible party
Sponsor
First posted
Mar 4, 2026
Start date
Mar 1, 2026
Primary completion
Mar 1, 2027 (estimated)
Completion
Mar 1, 2027 (estimated)
Last update
May 28, 2026

Study contacts

Melker Hagsäter, MD, MSc, PhD, PhD
Contact
melker.hagsater@vgregion.se
+46 3039 8000

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion